A case report of a patient with refractory adult-onset Still’s disease who was successfully treated with tocilizumab over 6 years

Hideko NakaharaLaboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University, 1-3 Yamada-oka, Suita, Osaka 565-0871, Japan;NTT West Osaka Hospital, 2-6-40 Karasugatsuji, Tennoji-ku, Osaka, Osaka 543-8922, Japan

Toru MimaLaboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University, 1-3 Yamada-oka, Suita, Osaka 565-0871, Japan

Naoko Yoshio-HoshinoLaboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University, 1-3 Yamada-oka, Suita, Osaka 565-0871, Japan

Masato MatsushitaDivision of Rheumatology, National Hospital Organization, Osaka Minami Medical Center, 2-1 Kidohigashi-cho, Kawachinagano, Osaka 586-8521, Japan

Jun HashimotoDepartment of Orthopaedics, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan

Norihiro NishimotoLaboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University, 1-3 Yamada-oka, Suita, Osaka 565-0871, JapanCorrespondence[email protected]

Abstract

Interleukin-6 overproduction is pathologically involved in adult onset Still’s disease (AOSD). We successfully treated a man with refractory AOSD utilizing tocilizumab. Tocilizumab was discontinued after 15 doses due to intestinal bleeding, but the efficacy was sustained over 21 months. Tocilizumab was readministered safely upon recurrence and showed similar efficacy over 6 years. Corticosteroid and NSAIDs could be discontinued and intestinal bleeding was no more observed. Tocilizumab can be a therapeutic option for AOSD.

Keywords::

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

A case report of a patient with refractory adult-onset Still’s disease who was successfully treated with tocilizumab over 6 years

Related Research Data

Information for

Open access

Opportunities

Help and information

A case report of a patient with refractory adult-onset Still’s disease who was successfully treated with tocilizumab over 6 years

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related Research Data

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature